SUVEN2023-04-012023-06-30 SUVEN2023-04-012023-06-30in-bse-fin:OneOperatingExpenses01Member SUVEN2023-04-012023-06-30in-bse-fin:OneOperatingExpenses02Member SUVEN2023-06-30 SUVEN2023-04-012023-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 530239 SUVEN NOTLISTED Suven Life Sciences Limited Equity 2023-04-01 2024-03-31 2023-08-08 2023-08-01 INR Lakhs First quarter 11:30:00 12:45:00 2023-08-08 2023-08-08 Not applicable Single segment The Company has only one business segment, i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented 2023-04-01 2023-06-30 Unaudited Standalone 37973000.00 56396000.00 94369000.00 0.00 0.00 0.00 45372000.00 512000.00 16645000.00 60546000.00 123075000.00 -28706000.00 0.00 -28706000.00 0.00 0.00 0.00 0.00 -28706000.00 0.00 0.00 0.00 0.00 -28706000.00 475000.00 -28231000.00 0.00 0.00 218074000.00 1 -0.13 -0.13 0.00 0.00 -0.13 -0.13 NOTES:- 1) The above financial results of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 08, 2023.The results for the quarter ended June 30, 2023 has been reviewed by our statutory auditors. 2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder. 3) The consolidated financial results include the results of the wholly Owned Subsidiary, Suven Neurosciences, Inc 4) The Company has only one business segment, i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented. 5) The Company has alloted 72691239 equity shares amounting to Rs.39980.18 lakhs through rights issue on November 16,2022. Summary of Utilisation of Proceeds of Rights issue Particulars Amount Rs.In lakhs Amout Raised through Rights Issue of Shares 39980.18 Less: Rights Issue Expenses -280.00 Less: Amount Utilised -15242.70 Balance Amount 24457.48 6) Pursuant to a fire accident on April 26, 2020 at Jeedimetla Plant , certain fixed assets and other contents in buildings was damaged. The Company has lodged Insurance claim and received claim till date an amount of Rs.12.00 crores from Insurance company. 7) The figures for the quarter ended March 31, 2023 are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures up to third quarter of the financial year. 8)The corresponding previous period figures have been regrouped / reclassified where ever necessary. Other Expenses 14772000.00 R & D Expenses 45774000.00 Items that will not be reclassified to profit & loss 475000.00 475000.00 0.00 0.00